UBS AM
BLRX

UBS AM’s BioLineRX BLRX Stock Holding History

UBS AM’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-50
Closed -$85K – 2582
2013
Q4 		$85K Buy
+50
New +$80.6K ﹤0.01% 2511

Other funds holding BLRX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS AM's BLRX Position: Q1 2014 in Review

UBS AM sold out of BioLineRX (BLRX) in Q1 2014, closing a stake of 50 shares — an estimated $85K sold.

UBS AM first reported a position in BLRX in Q4 2013 and held it in 1 quarter. The position peaked at $85K in Q4 2013. 19 funds tracked by Wall St. Rank hold BLRX as of Q1 2014.

  • UBS AM reported no remaining BioLineRX position as of Q1 2014 after selling out during the quarter.
  • UBS AM sold 50 BioLineRX shares in Q1 2014, an estimated $85K.
  • UBS AM first reported a position in BioLineRX in Q4 2013 and held it in 1 quarter.
  • UBS AM's BioLineRX position peaked at $85K in Q4 2013.
  • 19 funds tracked by Wall St. Rank held BioLineRX as of Q1 2014.

Based on UBS AM's 13F filing for Q1 2014, filed 23 May 2014.